AUPH Stock Summary and Trading Ideas (Aurinia Pharmaceuticals - Common Shares | NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.

Aurinia Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol AUPH.

As of January 28, 2025, AUPH stock price climbed to $8.33 with 516,812 million shares trading.

AUPH has a beta of 1.03, meaning it tends to be more sensitive to market movements. AUPH has a correlation of 0.07 to the broad based SPY ETF.

AUPH has a market cap of $1.19 billion. This is considered a Small Cap stock.

Last quarter Aurinia Pharmaceuticals - Common Shares reported $68 million in Revenue and $.10 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $.09.

In the last 3 years, AUPH traded as high as $20.48 and as low as $4.07.

The top ETF exchange traded funds that AUPH belongs to (by Net Assets): IWM, IWO, IBB, VTWO, VHT.

AUPH has underperformed the market in the last year with a return of +4.3%, while SPY returned +25.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in AUPH shares. However, AUPH has outperformed the market in the last 3 month and 2 week periods, returning +18.2% and +7.2%, while SPY returned +4.6% and +3.9%, respectively. This indicates AUPH has been having a stronger performance recently.

AUPH support price is $8.01 and resistance is $8.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AUPH shares will trade within this expected range on the day.